

## AUTHOR INDEX

**Abbott, R. R.** See Bhagchandani, L.

**Abbruzzese, J. L.** See Moor, D. F., Jr.; Pazdur, R.

**Adenis, A.**  
—Carlier, D.; Darloy, F.; Pion, J. M.; Bonneterre, J.; Demaille, A.; French Northern Oncology Group: Cytarabine and cisplatin as salvage therapy in patients with metastatic colorectal cancer who failed 5-fluorouracil + folinic acid regimen, 158

**Agarwala, S. S.**  
—Bahnson, R. R.; Wilson, J. W.; Szumowski, J.; Ernstoff, M. S.: Evaluation of the combination of vinblastine and quinidine in patients with metastatic renal cell carcinoma: A Phase I study, 211

**Ahmann, F.** See Marshall, M. E.

**Aitini, E.** See Di Leo, A.

**Ajani, J. A.** See Pazdur, R.

**Alessandroni, L.** See Arcangeli, G.

**Amato, S.** See Vallejo, C. T.

**Ambrogi, C.** See Arcangeli, G.

**Amir, G.** See Ron, I. G.

**Anderson, L.** See Krywicki, R.

**Anderson, P. J.** See Smith, D. E.

**Andresen, S. W.** See Kalaycioglu, M. E.

**Andrusis, I. L.** See Warner, E.

**Angelini, F.** See Arcangeli, G.

**Anscher, M. S.**  
—Prostate bed massage as a means to determine the source of a rising prostate specific antigen after radical prostatectomy, 481

**Antoine, E. C.**  
—Rixe, O.; Vuillemin, E.; Benhammouda, A.; Borel, C.; Ghironzi, G. C.; Mularoni, E.; Franks, C.; Auclerc, G.; Soubrane, C.; Banzet, P.; Weil, M.; Khayat, D.: A Phase II study of tamoxifen combined with cisplatin-interleukin 2 and alpha-interferon in metastatic melanoma, 509

**Antunovic, V.** See Jeremic, B.

**Aqual, S.** See Girdler, N. M.

**Arase, Y.** See Ikeda, K.

**Arcangeli, G.** See Arcangeli, G.

**—Angelini, F.; Arcangeli, G.; Tersigni, R.; D'Aprile, M.; Micheli, A.; Veltri, E.; Ambrogi, C.; Alessandroni, L.; Giovinazzo, G.; D'Angelo, L.**: A pilot study of concomitant protracted venous infusion 5-fluorouracil and hyperfractionated radiotherapy in rectal tumors, 369

**Asbury, R.**  
—Blessing, J. A.; Smith, D. M.; Carson, L. F.: Aminothiadiazole in the treatment of advanced leiomyosarcoma of the uterine corpus, 397

**Aszari, E.** See Federico, M.

**Ata, E.** See Malik, I. A.

**Athanassiou, A.** See Pectasides, D.

**Atlan, D.**  
—Chevallier, B.; Sheng, R. G.: Tamoxifen for the treatment of metastatic inflammatory breast carcinoma, 74

**Atree, S. V.**  
—Crilley, P. A.; Conroy, J. F.; Micaily, B.; Brodsky, J. T.: Cancer of the esophagus following allogeneic bone marrow transplantation for acute leukemia, 343

**Auclerc, G.** See Antoine, E. C.

**Ausili-Cefaro, G.**  
—Marmiroli, L.; Nardone, L.; Salvi, G.: Prolonged continuous infusion of carboplatin and concomitant radiotherapy in advanced head and neck cancer: A Phase I study, 273

**Avanzini, P.** See Federico, M.

**Aydiner, A.**  
—Bugra, Z.; Topuz, E.; Meric, M.: Acute myocardial infarction in man treated with epirubicin for non-Hodgkin lymphoma, 444

**Baert, L.** See Vandenbroucke, F.

**Bahnsen, R. R.** See Agarwala, S. S.

**Baillet, F.** See Maulard, C.

**Bajetta, E.** See Di Leo, A.

**Baker, T. R.** See Hempling, R. E.

**Bander, J. J.** See LoRusso, P. M.

**Banzet, P.** See Antoine, E. C.

**Barbieri, M. R.** See Vallejo, C. T.

**Belanger, R.** See Stewart, D. J.

**Benhammouda, A.** See Antoine, E. C.

**Benjamin, R. S.** See Kleinerman, E. S.; Patel, S. R.; Stewart, D. J.

**Benson, A. B., III** See Clark, J. L.

**Berruti, A.** See Dogliotti, L.

**Berry, M.** See Francois, A.

**Bertelli, G.** See Pronzato, P.

**Bertetto, O.** See Dogliotti, L.

**Bhagchandani, L.**  
—Sanadi, R. E.; Sattar, S.; Abbott, R. R.: Basal cell carcinoma presenting as a finger mass: A case report, 176

**Bian, A. R.** See Di Leo, A.

**Bielamowicz, S.** See Smith, D. E.

**Biganzoli, L.** See Di Leo, A.

**Billiet, I.** See Vandenbroucke, F.

**Birkhofer, M.** See Olver, I.

**Birnbaum, E.** See Myerson, R. J.

**Bishop, J.** See Olver, I.

**Bitran, J. D.**  
—Green, M.; Perry, M.; Hollis, D. R.; Herndon, J. E., II: A Phase II study of recombinant interferon-gamma following combination chemotherapy for patients with extensive small cell lung cancer, 67

**Black, P.** See Seegenschmidt, M. H.

**Blessing, J. A.** See Asbury, R.; Look, K. Y.; Malfetano, J. H.; Manetta, A.

**Blumenreich, M.** See Joseph, G.

**Blumenstein, B.** See Marshall, M. E.

**Bochicchio, A. M.** See Di Leo, A.

**Boege, F.** See Nemunaitis, J.

**Bolwell, B. J.** See Kalaycioglu, M. E.

**Bonnel, C.** See Caudry, M.

**Bonneterre, J.** See Adenis, A.

**Bookman, M.** See Broun, E. R.

**Borel, C.** See Antoine, E. C.

**Bowen, K.** See Krywicki, R.

**Brady, L. W.** See Seegenschmidt, M. H.

**Braly, P. D.** See McClay, E. F.

**Bready, B.** See Moor, D. F., Jr.; Pazdur, R.

**Broder, L. E.**  
—Sridhar, K. S.; Selawry, O. S.; Charyulu, K. N.; Rao, R. K.; Saldana, K. J.; Donnelly, E. J.; Raub, W. A., Jr.: A randomized clinical trial in bronchogenic small-cell carcinoma evaluating alternating maintenance therapy of vincristine, Adriamycin, procarbazine, and etoposide (VAPE) with cyclophosphamide, CCNU, and methotrexate (CCM) versus CCM maintenance alone in complete responders following VAPE induction and late intensification (Erratum), 462

**Brodsky, J. T.** See Atree, S. V.

**Broun, E. R.**

—Isseminger, K. A.; Bookman, M.: A Phase II trial of edatrexate in previously treated ovarian cancer, 164

**Brunel, P.** See Maulard, C.

**Bruno, S.**

—Puerto, V. L.; Mickiewicz, E.; Hegg, R.; Texeira, L. C.; Gaitan, L.; Martinez, L.; Fernandez, O.; Otero, J.; Kesselring, G.; Noguera, C.; Delgado, G.; Gaubert, P.; Delgado, F. M.; Solidoro, A.: Phase II trial of weekly IV vinorelbine as a single agent in first-line advanced breast cancer chemotherapy: The Latin-American experience, 392

**Bugra, Z.** See Aydiner, A.

**Burgess, M. A.** See Patel, S. R.

**Butt, A.** See Malik, I. A.

**Buzdar, A. U.** See Ibrahim, N. K.

**Buzzoni, E.** See Di Leo, A.

**Cabanillas, F. F.** See Herrada, J.

**Campbell, K.** See Stuart, K.

**Canlapian, D.** See Juillard, G.

**Cannata, G.** See Gebbia, V.

**Carencio, J.** See Caudry, M.

**Carlier, D.** See Adenis, A.

**Carpia, A.**

—Sagripanti, A.; Poddighe, R.; Gherarducci, G.; Nicolini, A.: Cancer incidence and mortality in patients with heart disease: Effect of oral anticoagulant therapy, 15

**Carrión, J. R.**

—García Arroyo, F. R.; Salinas, P.: Infusional chemotherapy (EPOCH) in patients with refractory or relapsed lymphoma, 44

**Carroll, R.** See Reddy, S. P.

**Carson, L. F.** See Asbury, R.

**Casselman, J.** See Vandenbergroucke, F.

**Cassileth, P.** See Friedenberg, W. R.

**Caudry, M.**

—Bonnel, C.; Floquet, A.; Marsault, C.; Quétin, P.; Pujol, J.; Maton, O.; Dujols, J.-P.; Caudry, Y.; Skawinski, P.; Carencio, J.; Mokhtari, F.; Célérier, D.; Quinton, A.; Demaux, H.; Maire, J.-P.: A randomized study of bolus fluorouracil plus folinic acid versus 21-day fluorouracil infusion alone or in association with cyclophosphamide and mitomycin C in advanced colorectal carcinoma, 118

**Caudry, Y.** See Caudry, M.

**Cavanna, L.** See Federico, M.

**Célérier, D.** See Caudry, M.

**Cellerino, R.** See Graziano, F.

**Chaitchik, S.** See Ron, I. G.

**Charyulu, K. N.** See Broder, L. E.

**Chatikhine, V. A.** See Francois, A.

**Chayama, K.** See Ikeda, K.

**Chen, S.-C.** See Keung, Y.-K.

**Chevallier, B.** See Atlant, D.; Francois, A.

**Chevrier, A.** See Francois, A.

**Cifarelli, R. A.** See Golucci, G.

**Clark, J. L.**

—Küçük, Ö.; Neuberg, D. S.; Benson, A. B., III; Taylor, S. G., IV; Pandya, K. J.; Mansour, E. G.; Douglass, H. O., Jr.; Haller, D. G.: Phase II trial of etoposide, doxorubicin, and cisplatin combination in advanced measurable gastric cancer, 318

**Class, R.**

—Book reviews, 90

**Clendeninn, N. J.** See Feun, L. G.

**Clerico, M.** See Dogliotti, L.

**Cobb, P.** See Krywicki, R.

**Coen, V.**

—Van Lancker, M.; De Neve, W.; Storme, G.: Prognostic factors in locoregional non-small cell lung cancer treated with radiotherapy, 111

**Comella, G.** See Di Leo, A.

**Conroy, J. F.** See Atree, S. V.

**Costa, M. A.** See Velasco, E.

**Court, W.** See Forman, J. D.

**Crawford, E. D.** See Marshall, M. E.

**Crilly, P. A.** See Atree, S. V.

**Crommelin, M. A.** See Martijn, H.

**Cuevas, M. A.** See Vallejo, C. T.

**Dahrouge, S.** See Evans, W. K.; Steward, D. J.

**D'Angelo, L.** See Arcangeli, G.

**D'Aprire, M.** See Arcangeli, G.; Di Leo, A.

**Darloy, F.** See Adenis, A.

**De Coene, N.** See Van Lancker, M.

**De Neve, W.** See Coen, V.

**de Neve, W.** See Martijn, H.

**de Souza, P. L.**

—Friedlander, M. L.: Humoral hypercalcemia associated with adenocarcinoma of the rectum: A case report and review of the literature, 126

**Delanian, S.** See Maulard, C.

**Delgado, F. M.** See Bruno, S.

**Delgado, G.** See Bruno, S.

**Delpach, B.** See Francois, A.

**Demaille, A.** See Adenis, A.

**Demeaux, H.** See Caudry, M.

**Derluy, J.** See Vandenbergroucke, F.

**Devi, S.** See Forman, J. D.

**Di Gregorio, C.** See Gebbia, V.

**Di Lallo, A.** See Di Leo, A.

**Di Leo, A.**

—Bajetta, E.; Buzzoni, R.; Bochicchio, A. M.; Nolè, F.; Biganzoli, L.; D'Aprire, M.; Veltri, E.; Comella, G.; Aitini, E.; Di Lallo, A.; Santini, M.; Luccarelli, S.; Bian, A. R.: Epirubicin plus medroxyprogesterone as second-line treatment of advanced prostatic cancer, 239

**Di Renzo, N.** See Federico, M.

**Dimitriadis, M.** See Pectasides, D.

**Dion, J. E.** See Larner, J. M.

**Djuric, L.** See Jeremic, B.

**Dogliotti, L.**

—Bertetto, O.; Berruti, A.; Clerico, M.; Fanchini, L.; Sicora, W.; Faggiuolo, R.: Combination chemotherapy with carboplatin and methotrexate in the treatment of advanced urothelial carcinoma: A Phase II study, 78

**Donnelly, E. J.** See Broder, L. E.

**Douglass, H. O., Jr.** See Clark, J. L.

**Dujols, J.-P.** See Caudry, M.

**Eijkenboom, W. M. H.** See van Mierlo, I. J.

**Einstein, A. B.** See Marshall, M. E.

**Eisenberger, M.** See Marshall, M. E.

**Endoh, M.** See Ogoshi, K.

**Ernstoff, M. S.** See Agarwala, S. S.

**Espinosa-Jacobs, M. C.**

—Suntharalingam, M.; Eisenberger, M.; Sinibaldi, V.; Salazar, O. M.: Combined carboplatin plus bleomycin and conventional radiotherapy for advanced carcinomas of the head and neck, 52

**Evans, W. K.** See Stewart, D. J.

**Radwi, A.; Tomiak, E.; Logan, D. M.; Martins, H.; Stewart, D. J.; Goss, G.; Maroun, J. A.; Dahrouge, S.**: Oral etoposide and carboplatin: Effective therapy for elderly patients with small cell lung cancer, 149

**Faggiuolo, R.** See Dogliotti, L.

**Falkson, G.**

—Lipsitz, S.; Borden, E.; Simson, I.; Haller, D.: Hepatocellular car-

cinoma: An ECOG randomized Phase II study of beta-interferon and menagoril, 287

**Fanchini, L.** See Dogliotti, L.

**Federico, M.**

- Gobbi, P. G.; Moretti, G.; Avanzini, P.; Di Renzo, N.; Cavanna, L.; Ascari, E.; Silingardi, V.: Effects of thymostimulin with combination chemotherapy in patients with aggressive non-Hodgkin's lymphoma, 8

**Ferlazzo, G.**

- Magno, C.; Lupo, G.; Rizzo, M.; Iemmo, R.; Semino, C.; Melioli, G.: A Phase I study of intravesical continuous perfusion of recombinant interleukin-2 in patients with superficial bladder cancer, 100

**Fernandez, O.** See Bruno, S.

**Fernández-Trigo, V.**

- Shamsa, F.; Vidal-Jové, J.; Kern, D. H.; Sugarbaker, P. H.: Prognostic implications chemoresistance-sensitivity assays for colorectal and appendiceal cancer, 454

**Feun, L. G.**

- Robinson, W. A.; Savaraj, N.; Gonzalez, R.; Liebmann, A.; Offenbacher, K.; Clendeninn, N. J.: Phase II trial of piritrexim and DTIC using an alternating dose schedule in metastatic melanoma, 488

**Fiorentino, B.** See Iacobelli, S.

**Fleshman, J.** See Myerson, R. J.

**Floquet, A.** See Caudry, M.

**Flores, M. R.**

- Sridhar, K. S.; Thurer, R. J.; Saldana, M.; Raub, W. A., Jr.; Klimas, N. G.: Lung cancer in patients with human immunodeficiency virus infection, 59

**Forman, J. D.**

- Warmelink, C.; Devi, S.; Court, W.; Sharma, R.; Yudeluv, M.; Porter, A. T.; Maughan, R.: Alternating conformal neutron and photon irradiation for locally advanced adenocarcinoma of the prostate, 231

**Formenti, S. C.**

- Lucas, G.; Ibarra, J. A.; Langholz, B.; Syed, N. M.; Puthawala, A. A.; Neblett, D.; Gowdy, R. A.; Petrovich, Z.: Initial brachytherapy in the breast conservation approach to breast cancer, 331

**Francois, A.**

- Chatikhine, V. A.; Chevallier, B.; Ren, G. S.; Berry, M.; Chevrier, A.; Delpech, B.: Neuroendocrine primary small cell carcinoma of the breast: Report of a case and review of the literature, 133

**Franks, C.** See Antoine, E. C.

**Friedenberg, W. R.**

- Miller, H. J.; Marx, J. J., Jr.; Schloesser, L. L.; Reding, D. J.; Massa, J. J.; Hocking, W. G.; Mercier, R. J.; Raich, P. C.; Cassileth, P. A.: The treatment of older adult patients with acute myeloid leukemia by triple infusion chemotherapy, 105

**Friedlander, M. L.** See de Souza, P. L.

**Fry, R.** See Myerson, R. J.

**Gaitan, L.** See Bruno, S.

**Gano, J. B.** See Kleinerman, E. S.

**García Arroyo, F. R.** See Carrón, J. R.

**Garland, D.** See Krywicki, R.

**Garufi, C.** See Iacobelli, S.

**Gastineau, D. A.** See Letendre, L.

**Gaubert, P.** See Bruno, S.

**Gebbia, N.** See Gebbia, V.

**Gebbia, V.**

- Testa, A.; Di Gregorio, C.; Ingria, F.; Valenza, R.; Cannata, G.; Moschella, F.; Restivo, G.; Gebbia, N.: Vinorelbine plus cisplatin in recurrent or previously untreated unresectable squamous cell carcinoma of the head and neck, 293

**Gertz, M. A.**

- Kalish, L. A.; Kyle, R. A.; Hahn, R. G.; Tormey, D. C.; Oken, M. M.: Phase III study comparing vincristine, doxorubicin (Adriamycin), and dexamethasone (VAD) chemotherapy with VAD plus recombinant interferon alfa-2 refractory or relapsed multiple myeloma, 475

**Getty, L.** See Nemunaitis, J.

**Gherarducci, G.** See Carpi, A.

**Ghirtoni, G. C.** See Antoine, E. C.

**Giotta, F.** See Golucci, G.

**Giovinazzo, G.** See Arcangeli, G.

**Girdler, N. M.**

- McGurk, M.; Aqual, S.; Prince, M.: The effect of epidermal growth factor mouthwash on cytotoxic-induced oral ulceration: A phase I clinical trial, 403

**Giuliani, F.** See Golucci, G.

**Gobbi, P. G.** See Federico, M.

**Golucci, G.**

- Giotta, F.; Maiello, E.; Cifarelli, R. A.; Leo, S.; Giuliani, F.; Pezzella, G.; Pedicini, A.; Valorì, V.: Efficacy of the association of folinic acid and 5-fluorouracil alone versus folinic acid and 5-fluorouracil plus 4-epidoxorubicin in the treatment of advanced gastric carcinoma, 519

**Gonzalez, R.** See Feun, L. G.

**Goor, C.** See Van Lancker, M.

**Goss, G.** See Evans, W. K.

**Gowdy, R. A.** See Formenti, S. C.

**Gralla, R. J.** See Rivera, M. P.

**Gramazio, A.** See Graziano, F.

**Graziano, F.**

- Cellerino, R.; Menestrina, F.; Nicoli, N.; Gramazio, A.; Latini, L.; Piga, A.: Synchronous primary hepatic lymphoma and epidermoid lung carcinoma treated with chemotherapy and surgery, 194

**Green, J. P.** See Sutton, J. B.

**Green, M.** See Bitran, J. D.; Olver, I.

**Greven, K. M.** See Mumber, M. P.

**Groshen, S.** See Keung, Y.-K.

**Grujicic, D.** See Jeremic, B.

**Hadley, T.** See Joseph, G.

**Hahn, R. G.** See Gertz, M. A.

**Haller, D. G.** See Clark, J. L.

**Hamm, J.** See Joseph, G.

**Hartmann, L. C.** See Ingle, J. N.

**Heelan, R. T.** See Miller, V. A.

**Hegg, R.** See Bruno, S.

**Heitzel, M.** See Sutton, J. B.

**Hemping, R. E.**

- Piver, M. S.; Baker, T. R.: Impact of progression-free survival of adjuvant cyclophosphamide, vincristine, doxorubicin (Adriamycin), and dacarbazine (CYVADIC) chemotherapy for stage I uterine sarcoma: A prospective trial, 282

**Hendler, F.** See Joseph, G.

**Herndon, J. E., II** See Bitran, J. D.

**Herrada, J.**

- Cabanillas, F. F.: Multicentric Castleman's disease, 180

**Hoagland, H. C.** See Letendre, L.

**Hocking, W. G.** See Friedenberg, W. R.

**Hollis, D. R.** See Bitran, J. D.

**Homesley, H. D.** See Malfetano, J. H.

**Hosokawa, M.** See Kawata, A.

**Housset, M.** See Maulard, C.

**Howell, S. B.** See McClay, E. F.

**Hsu, C.-Y.** See Lin, J.-C.

**Huberman, M.** See Stuart, K.

**Hussein, A.** See Mudad, R.

**Iacobelli, S.**

- Garufi, C.; Irtelli, L.; Martino, M. T.; Santobuono, F.; Vicario, G.; Tinari, N.; Fiorentino, B.; Innocenti, P.; Natoli, C.: A Phase I study of recombinant interferon- $\alpha$  administered as a seven-day

continuous venous infusion at circadian-rhythm modulated rate in patients with cancer, 27

**Ibarra, J. A.** See Formenti, S. C.

**Ibrahim, N. K.**

—Buzdar, A. U.: Aromatase inhibitors: Current status, 407

**Iemmo, R.** See Ferlazzo, G.

**Ikeda, K.**

—Saitoh, S.; Koida, I.; Tsubota, A.; Arase, Y.; Chayama, K.; Kumada, H.: A prospective randomized evaluation of a compound of tegafur and uracil as an adjuvant chemotherapy for hepatocellular carcinoma treated with transcatheter arterial chemoembolization, 204

**Inbar, M. J.** See Ron, I. G.

**Ingle, J. N.**

—Krook, J. E.; Maillard, J. A.; Hartmann, L. C.; Wieand, H. S.: Evaluation of ifosfamide plus mesna as first-line chemotherapy in women with metastatic breast cancer, 498

**Ingris, R.** See Gebbia, V.

**Innocenti, P.** See Iacobelli, S.

**Irtelli, L.** See Iacobelli, S.

**Iseminger, K. A.** See Broun, E. R.

**Isono, K.** See Ogoshi, K.

**Jaffe, N.** See Kleinerman, E. S.

**Jan, J.-S.** See Lin, J.-C.

**Jane, J. A.** See Larner, J. M.

**Jansen, P. P.** See van Mierlo, I. J.

**Jenkins, T.** See Krywicki, R.

**Jennings, L. W.** See Nemunaitis, J.

**Jensen, M. E.** See Larner, J. M.

**Jeremic, B.**

—Grujicic, D.; Antunovic, V.; Djuric, L.; Shibamoto, Y.: Accelerated hyperfractionated radiation therapy or malignant glioma: A phase II study, 449

**Johnston, D. A.** See Kleinerman, E. S.

**Jones, A. S.**

—The untreated patient with squamous carcinoma of the head and neck, 363

**Jones, D., III** See Moor, D. F., Jr.; Pazdur, R.

**Jose, B.** See Seither, R. B.

**Joseph, G.**

—Hamm, J.; Morris, K.; Seeger, J.; Blumenreich, M.; Hadley, T.; Hendler, F.; Woodcock, T.: Phase II trial of 5-fluorouracil, folinic acid, and N,N1, N11-triethylenethiophosphoramide (thiotepa) in patients with advanced breast cancer, 385

**Juillard, G.**

—Padua, D.; Canlapian, D.; McBride, W.: Resistance to common viruses during intralymphatic injections of tumor cell vaccines: correlation with circulating cytokines, 226

**Kagan, A. R.** See Smith, D. E.

**Kalaycioglu, M. E.**

—Lichtin, A. E.; Andresen, S. W.; Tuason, L.; Bolwell, B. J.: High-dose busulfan and cyclophosphamide followed by autologous bone marrow transplantation and/or peripheral blood progenitor cell rescue for metastatic breast cancer, 491

**Kalish, L. A** See Gertz, M. A.

**Karlsson, U. L.** See Seegenschmiedt, M. H.

**Karp, A. H.** See Sutton, J. B.

**Kawata, A.**

—Une, Y.; Hosokawa, M.; Wakizaka, Y.; Namieno, T.; Uchino, J.; Kobayashi, H.: Adjuvant chemoimmunotherapy for hepatocellular carcinoma patients, 257

**Kennedy, B. J.**

—Torkelson, J.: Optimal number of chemotherapy courses in advanced nonseminomatous testicular carcinoma, 463

**Kern, D. H.** See Fernández-Trigo, V.

**Kessehring, G.** See Bruno, S.

**Ketelbey, W.** See Olver, I.

**Keung, Y.-K.**

—Watkins, K.; Chen, S.-C.; Groshen, S.; Levine, A. M.; Douer, D.: Increased incidence of central venous catheter-related infections in bone marrow transplant patients, 469

**Khan, M. A.** See Malik, I. A.

**Khan, W. A.** See Malik, I. A.

**Khayat, D.** See Antoine, E. C.

**Kim, S.** See McClay, E. F.

**Kirmani, S.** See McClay, E. F.

**Kleinerman, E. S.**

—Gano, J. B.; Johnston, D. A.; Benjamin, R. S.; Jaffe, N.: Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma, 93

**Klimas, N. G.** See Flores, M. R.

**Klocker, J.**

—Sabitzer, H.; Raunik, W.; Wieser, S.; Schumer, J.: Combined application of cisplatin, vindesine, hyaluronidase and radiation for treatment of advanced squamous cell carcinoma of the head and neck, 425

**Kobayashi, H.** See Kawata, A.

**Kodner, I.** See Myerson, R. J.

**Koida, I.** See Ikeda, K.

**Kondo, M.** See Nishida, K.

**Kris, M. G.** See Miller, V. A.; Rivera, M. P.

**Krook, J. E.** See Ingle, J. N.

**Krywicki, R.**

—Bowen, K.; Anderson, L.; Garland, D.; Cobb, P.; Jenkins, T.; O'Rourke, T.: Mixed-lineage acute myeloid leukemia associated with a suprasellar dysergic tumor, 83

**Küçük, Ö.** See Clark, J. L.

**Kumada, H.** See Ikeda, K.

**Kyle, R. A.** See Gertz, M. A.

**Lacava, J. A.** See Vallejo, C. T.

**Lacey, D.** See Myerson, R. J.

**Lad, T.** See Reddy, S. P.

**Lamote, J.** See Van Lancker, M.

**Landolt-Weber, U.** See Stey, C.

**Landucci, M.** See Pronzato, P.

**Langhi, M. J.** See Vallejo, C. T.

**Langholz, B.** See Formenti, S. C.

**Larner, J. M.**

—Phillips, C. D.; Dion, J. E.; Jensen, M. E.; Newman, S. A.; Jane, J. A.: A Phase I-II trial of superselective carboplatin, low-dose infusional 5-fluorouracil and concurrent radiation for high-grade gliomas, 1

**Latini, L.** See Graziano, F.

**Leo, S.** See Golucci, G.

**Leone, B. A.** See Vallejo, C. T.

**Letendre, L.**

—Noel, P.; Tefferi, A.; Solberg, L. A., Jr.; Gastineau, D. A.; Hoagland, H. C.: Continuous infusion etoposide/carboplatin for treatment of refractory acute leukemia, 382

**Levendag, P. C.** See van Mierlo, I. J.

**Levin, B.** See Pazdur, R.

**Levine, A. M.** See Keung, Y.-K.

**Levitt, M. L.** See Schiller, J. H.

**Lichtin, A. E.** See Kalaycioglu, M. E.

**Liebmann, A.** See Feun, L. G.

**Lin, J.-C.**

—Jan, J.-S.; Hsu, C.-Y.: Neoadjuvant chemotherapy for advanced nasopharyngeal carcinoma, 139

**Lindberg, R. D.** See Seither, R. B.

**Linker, K. A.** See Patel, S. R.

**Lippman, S. M.** See Moor, D. F., Jr.

**Logan, D. M.** See Evans, W. K.

**Loman, P. L.** See LoRusso, P. M.

**Look, K. Y.** See Manetta, A.

—Blessing, J. A.; Williams, L.; Morris, M.: A phase II trial of mepabone (NSC 336628) as salvage therapy for squamous cell carcinoma of the cervix, 441

—Muss, H. B.; Blessing, J. A.; Morris, M.: A Phase II trial of 5-fluorouracil and high-dose leucovorin in recurrent epithelial ovarian carcinoma, 19

Lopez, M. See Myerson, R. J.

LoRusso, P. M.

—Lomen, P. L.; Redman, B. G.; Poplin, E.; Bander, J. J.; Valdivieso, M.: Phase I study of monoclonal antibody-ricin A chain immunoconjugate Xomazyme-791 in patients with metastatic colon cancer, 307

Louie, D. See Sutton, J. B.

Lucas, G. See Formenti, S. C.

Luccarelli, S. See Di Leo, A.

Lupo, G. See Ferlazzo, G.

Lybeert, M. L. M. See Martijn, H.

MacDonald, J. S. See Williamson, S. K.

Machiavelli, M. R. See Vallejo, C. T.

Maddox, A.-M. See Williamson, S. K.

Magno, C. See Ferlazzo, G.

Maiello, E. See Golucci, G.

Maillard, J. A. See Ingle, J. N.

Maire, J.-P. See Caudry, M.

Malftano, J. H.

—Blessing, J. A.; Homesley, H. D.: A phase II trial of gallium nitrate (NSC #15200) in nonsquamous cell carcinoma of the cervix, 495

Malik, I. A.

—Khan, W. A.; Qazilbash, M.; Ata, E.; Butt, A.; Khan, M. A.: Clinical efficacy of lorazepam in prophylaxis of anticipatory, acute, and delayed nausea and vomiting induced by high doses of cisplatin, 170

Manetta, A.

—Blessing, J. A.; Look, K. Y.: A Phase II study of fazarabine in patients with advanced ovarian cancer, 156

—Blessing, J. A.; Mann, W. J.; Smith, D. M.: A phase II study of fazarabine (NSC 281272) in patients with advanced squamous cell carcinoma of the cervix, 439

Mann, W. J. See Manetta, A.

Mansour, E. G. See Clark, J. L.

Marincek, B. See Stey, C.

Markham, M. See Sklarin, N. T.

Markowitz, A. See Pazdur, R.

Marks, J. E. See Reddy, S. P.

Marmiroli, L. See Ausili-Cefaro, G.

Maroun, J. A. See Evans, W. K.

Marsault, C. See Caudry, M.

Marshall, M. E.

—Wolf, M. K.; Crawford, E. D.; Weiss, G. R.; Ahmann, F.; Meyers, F. J.; Blumenstein, B.; Eisenberger, M.; Einstein, A. B.: Phase II trial of CHIP for the treatment of advanced, hormonally refractory carcinoma of the prostate, 400

Martijn, H.

—de Neve, W.; Lybeert, M. L. M.; Crommelin, M. A.; Ribot, J. G.: Adjuvant postoperative radiotherapy for adenocarcinoma of the rectum and rectosigmoid: a retrospective analysis of locoregional control, survival, and prognostic factors on 178 patients, 277

Martinez, L. See Bruno, S.

Martino, M. T. See Iacobelli, S.

Martins, C. A. See Velasco, E.

Martins, H. See Evans, W. K.

Marx, J. J., Jr. See Friedenberg, W. R.

Maton, O. See Caudry, M.

Maughan, R. See Forman, J. D.

Maulard, C.

—Housset, M.; Brunel, P.; Delanian, S.; Taurelle, R.; Baillet, F.: Use of perioperative or split-course interstitial brachytherapy techniques for salvage irradiation of isolated local recurrences after conservative management of breast cancer, 348

Mazza, J. J. See Friedenberg, W. R.

McBride, W. See Juillard, G.

McClay, E. F.

—Braly, P. D.; Kirmani, S.; Plaxe, S. C.; Kim, S.; McClay, M. E.; Wilgus, L.; Howell, S. B.: A Phase II trial of intraperitoneal high-dose carboplatin and etoposide with granulocyte macrophage-colony stimulating factor support in patients with ovarian carcinoma, 23

McClay, M. E. See McClay, E. F.

McGurk, M. See Girdler, N. M.

Meeuwis, C. A. See van Mierlo, I. J.

Melioli, G. See Ferlazzo, G.

Menestrina, F. See Graziano, F.

Mercier, R. J. See Friedenberg, W. R.

Meric, M. See Aydiner, A.

Meyer, J. L. See Sutton, J. B.

Meyer, W. See Nemunaitis, J.

Meyers, F. J. See Marshall, M. E.

Micaily, B. See Atree, S. V.

Micheli, A. See Arcangeli, G.

Mickiewicz, E. See Bruno, S.

Miller, H. J. See Friedenberg, W. R.

Miller, V. A.

—Rigas, J. R.; Pisters, K. M. W.; Pfister, D. G.; Heelan, R. T.; Kris, M. G.: Ifosfamide plus high-dose cisplatin in patients with non-small cell lung cancer previously treated with chemotherapy, 303

Mitomi, T. See Ogoshi, K.

Mokhtari, F. See Caudry, M.

Moore, D. F., Jr.

—Pazdur, R.; Sugarman, S.; Jones, D., III; Lippman, S. M.; Bready, B.; Abbruzzese, J. L.: Pilot phase II trial of 13-cis-retinoic acid and interferon- $\alpha$  combination therapy for advanced pancreatic adenocarcinoma, 525

Moretti, G. See Federico, M.

Morgan-Ihring, C. See Schiller, J. H.

Morris, K. See Joseph, G.

Morris, M. See Look, K. Y.

Moschella, F. See Gebbia, V.

Moutzourides, G. See Pectasides, D.

Mudad, R.

—Hussein, A.; Peters, W. P.: Guillain-Barre syndrome following autologous bone marrow transplantation, 167

Mularoni, E. See Antoine, E. C.

Mullane M. See Reddy S. P.

Mumber, M. P.

—Greven, K. M.: Control of advanced chemodectomas of the head and neck with irradiation, 389

Muss, H. B. See Look, K. Y.

Myerson, R.J.

—Shapiro, S. J.; Lacey, D.; Lopez, M.; Birnbaum, E.; Fleshman, J.; Fry, R.; Kodner, I.: Carcinoma of the anal canal, 32

Nag, S.

—The evolving role of brachytherapy in breast cancer, 353

Nakamoto, H. See Nishida, K.

Namieno, T. See Kawata, A.

Namura, K. See Nishida, K.

Nardone, L. See Ausili-Cefaro, G.

Natoli, C. See Iacobelli, S.

Neblett, D. See Formenti, S. C.

Nemunaitis, J.

—Rosenfeld, C.; Getty, L.; Boegel, F.; Meyer, W.; Jennings, L. W.; Zeigler, Z.; Shadduck, R.: Pentoxifylline and ciprofloxacin in patients with myelodysplastic syndrome: A Phase II trial, 189

Neuberg, D. S. See Clark, J. L.

Newman, S. A. See Larner, J. M.

Nicoli, N. See Graziano, F.  
 Nicolini, A. See Carpi, A.  
 Nishida, K.  
 —Takano, H.; Ohtsuki, T.; Yoneda, M.; Nakamoto, H.; Terasawa, Y.; Yamane, E.; Nishioka, B.; Namura, K.; Yoshikawa, T.; Kondo, M.: Flow cytometric analysis of nuclear DNA content in the endoscopic biopsy tissues of gastric cancer, 325  
 Nishioka, B. See Nishida, K.  
 Noel, P. See Letendre, L.  
 Noguera, C. See Bruno, S.  
 Nolè, F. See Di Lso, A.  
 Nowak, P. J. C. M. See van Mierlo, I. J.  
 Nucci, M. See Velasco, E.

Offenhauser, K. See Feun, L. G.  
 Ogoshi, K.  
 —Satou, H.; Isono, K.; Mitomi, T.; Endoh, M.; Sugita, M.: Immunotherapy for esophageal cancer: A randomized trial in combination with radiotherapy and radiochemotherapy, 216  
 Ohtsuki, T. See Nishida, K.  
 Olver, I.  
 —Green, M.; Peters, W.; Zimet, A.; Toner, G.; Bishop, J.; Ketelbey, W.; Rastogi, R.; Birkhofer, M.: A Phase II trial of zeniplatin in metastatic melanoma, 56  
 O'Rourke, T. See Krywicki, R.  
 Otero, J. See Bruno, S.

Padua, D. See Juillard, G.  
 Pandya, K. J. See Clark, J. L.  
 Papadopoulos, N. E. See Patel, S. R.  
 Paridaens, R. See Vandenbroucke, F.  
 Paris, K. J. See Seither, R. B.  
 Patel, S. R.  
 —Burgess, M. A.; Papadopoulos, N. E.; Linke, K. A.; Benjamin, R. S.: Extraskeletal myxoid chondrosarcoma: Long-term experience with chemotherapy, 161  
 —Plager, C.; Papadopoulos, N. E.; Benjamin, R. S.: Myxoid malignant fibrous histiocytoma: Experience with chemotherapy, 528  
 Pazdur, R. See Moor, D. F., Jr.  
 —Bready, B.; Ajani, J. A.; Abbruzzese, J. L.; Markowitz, A.; Sugarmann, S.; Jones, D.; Levin, B.: Phase II trial of isotretinoin and recombinant interferon alfa-2a in metastatic colorectal carcinoma, 436  
 Pectasides, D.  
 —Moutzourides, G.; Dimitriadis, M.; Varthalitis, J.; Athanassiou, A.: Chemotherapy for Merkel cell carcinoma with carboplatin and etoposide, 418  
 Peddada, A. V. See Smith, D. E.  
 Pedicini, A. See Golucci, G.  
 Pei, Y. See Warner, E.  
 Perez, J. E. See Vallejo, C. T.  
 Perry, M. See Bitran, J. D.  
 Peters, W. See Olver, I.  
 Peters, W. P. See Mudad, R.  
 Petrovich, Z. See Formenti, S. C.  
 Pezzella, G. See Golucci, G.  
 Pfister, D. G. See Miller, V. A.  
 Phillips, C. D. See Larner, J. M.  
 Piga, A. See Graziano, F.  
 Pion, J. M. See Adenis, A.  
 Pisters, K. M. W. See Miller, V. A.  
 Piver, M. S. See Hempeling, R. E.  
 Plager, C. See Patel, S. R.  
 Plaxe, S. C. See McClay, E. F.  
 Poddighe, R. See Carpi, A.  
 Popelier, G. See Vandenbroucke, F.  
 Poplin, E. See LoRusso, P. M.  
 Porter, A. T. See Forman, J. D.

Posner, M. See Stuart, K.  
 Prince, M. See Girdler, N. M.  
 Pronzato, P.  
 —Landucci, M.; Vaira, F.; Vigani, A.; Bertelli, G.: Carboplatin, methotrexate, and vinblastine in outpatients with advanced transitional cell carcinoma of the bladder, 223  
 Puerto, V. L. See Bruno, S.  
 Pujol, J. See Caudry, M.  
 Puthawala, A. A. See Formenti, S. C.

Qazilbash, M. See Malik, I. A.  
 Quétin, P. See Caudry, M.  
 Quinton, A. See Caudry, M.

Rabinovich, M. G. See Vallejo, C. T.  
 Radwi, A. See Evans, W. K.  
 Raich, P. C. See Friedenberg, W. R.  
 Rao, R. K. See Broder, L. E.  
 Rastogi, R. See Olver, I.  
 Raub, W. A., Jr. See Broder, L. E.; Flores, M. R.  
 Raunik, W. See Klocker, J.  
 Reddy, S. P.  
 —Lad, T.; Mullane, M.; Rosen, F.; Carroll, R.; Marks, J. E.: Radiotherapy alone compared with radiotherapy and chemotherapy in patients with squamous cell carcinoma of the esophagus, 376  
 Reding, D. J. See Friedenberg, W. R.  
 Redman, B. G. See LoRusso, P. M.  
 Ren, G. S. See Francois, A.  
 Restivo, G. See Gebbia, V.  
 Ribot, J. G. See Martijn, H.  
 Rigas, J. R. See Miller, V. A.  
 Rivera, M. P.  
 —Kris, M. G.; Gralla, R. J.; White, D. A.: Syndrome of acute dyspnea related to combined mitomycin plus vinca alkaloid chemotherapy, 245  
 Rixe, O. See Antoine, E. C.  
 Rizzo, M. See Ferlazzo, G.  
 Robinson, W. A. See Feun, L. G.  
 Rodriguez, R. See Vallejo, C. T.  
 Roelstraete, A. See Van Lancker, M.  
 Romero, A. D. See Vallejo, C. T.  
 Romero Acuña, J. See Vallejo, C. T.  
 Romero Acuña, L. A. See Vallejo, C. T.  
 Ron, I. G.  
 —Amir, G.; Inbar, M. J.; Chaitchik, S.: Clear cell chondrosarcoma of rib following repetitive low-impact trauma, 87  
 Rosen, F. See Reddy, S. P.  
 Rosenfeld, C. See Nemunaitis, J.

Sabitzer, H. See Klocker, J.  
 Sacre, R. See Van Lancker, M.  
 Sagripanti, A. See Carpi, A.  
 Saitoh, S. See Ikeda, K.  
 Saldana, M. See Flores, M. R.  
 Saldana, M. J. See Broder, L. E.  
 Salinas, P. See Carrón, J. R.  
 Salvi, G. See Ausili-Cefaro, G.  
 Sanadi, R. E. See Bhagchandani, L.  
 Santini, M. See Di Leo, A.  
 Santobuono, F. See Iacobelli, S.  
 Satou, K. See Ogoshi, K.  
 Sattar, S. See Bhagchandani, L.  
 Sauter, C. See Stey, C.  
 Savaraj, N. See Feun, L. G.  
 Schellhammer, P. F.  
 —Patient counseling regarding treatment of T1/2 (A/B) prostate cancer, 532

**Schiller, J. H.**  
—Morgan-Ihring, C.; Levitt, M. L.: Concomitant administration of interleukin-2 plus tumor necrosis factor in advanced non-small cell lung cancer, 47

**Schloesser, L. I.** See Friedenberg, W. R.

**Schumer, J.** See Klocker, J.

**Seegenschmiedt, M. H.**  
—Karlsson, U. L.; Black, P.; Brady, L. W.: Thermoradiotherapy for brain tumors, 510

**Seeger, J.** See Joseph, G.

**Seither, R. B.**  
—Jose, B.; Paris, K. J.; Lindberg, R. D.; Spanos, W. J.: Results of irradiation in patients with high-grade gliomas evaluated by magnetic resonance imaging, 297

**Selawry, O. S.** See Broder, L. E.

**Semino, C.** See Ferlazzo, G.

**Seydel, H. G.**  
—Book review, 91

**Shadduck, R.** See Nemunaitis, J.

**Shamsa, F.** See Fernández-Trigo, V.

**Shapiro, S. J.** See Myerson, R. J.

**Sharma, R.** See Forman, J. D.

**Sheng, R. G.** See Atlan, D.

**Shetty, M. R.**  
—Letter to the editor, 543

**Shibamoto, Y.** See Jeremic, B.

**Sicora, W.** See Dogliotti, L.

**Silingardi, V.** See Federico, M.

**Skawinski, P.** See Caudry, M.

**Sklarin, N. T.**  
—Markham, M.: Spontaneous recurrent tumor lysis syndrome in breast cancer, 71

**Skorecki, K. L.** See Warner, E.

**Smith, D. E.**  
—Bielamowicz, S.; Kagan, A. R.; Anderson, P. J.; Peddada, A. V.: Cutaneous neuroendocrine (Merkel cell) carcinoma: A report of 35 cases, 199

**Smith, D. M.** See Asbury, R.; Manetta, A.

**Solberg, L. A., Jr.** See Letendre, L.

**Solidoro, A.** See Bruno, S.

**Soltys, K. M.** See Stewart, D. J.

**Soubrane, C.** See Antoine, E. C.

**Spanos, W. J.** See Seither, R. B.

**Spiridonidis, C. H.** See Williamson, S. K.

**Sridhar, K. S.** See Broder, L. E.; Flores, M. R.

**Stewart, D. J.** See Evans, W. K.

—Belanger, R.; Benjamin, R. S.: Prolonged disease-free survival following surgical debulking and high-dose cisplatin/doxorubicin in a patient with bulky metastases from giant cell tumor refractory to "standard" chemotherapy, 144

—Dahrouge, S.; Soltys, K. M.; Evans, W. K.: A Phase II study of 5-fluorouracil plus high-dose folinic acid in the treatment of recurrent small cell lung cancer, 130

**Stey, C.**  
—Landolt-Weber, U.; Vetter, W.; Sauter, C.; Marincek, B.: Malignant peritoneal mesothelioma after thorotrast exposure, 313

**Storme, G.** See Coen, V.; Van Lancker, M.

**Stuart, K.**  
—Posner, M.; Campbell, K.; Huberman, M.: Cisplatin and chronic oral etoposide as salvage therapy for advanced colorectal carcinoma, 300

**Sugarbaker, P.H.** See Fernández-Trigo, V.

**Sugarman, S.** See Moor, D. F., Jr.; Pazdur, R.

**Sugita, M.** See Ogoshi, K.

**Sutton, J. B.**  
—Green, J. P.; Meyer, J. L.; Louie, D.; Heltzel, M.; Karp, A. H.: Nasopharyngeal carcinoma: A study examining Asian patients treated in the United States, 337

**Syed, N. M.** See Formenti, S. C.

**Szumowski, J.** See Agarwala, S. S.

**Takano, H.** See Nishida, K.

**Tangen, C. M.** See Williamson, S. K.

**Taurelle, R.** See Maulard, C.

**Taylor, S. G., IV** See Clark, J. L.

**Tefferi, A.** See Letendre, L.

**Terasawa, Y.** See Nishida, K.

**Tersigni, R.** See Arcangeli, G.

**Testa, A.** See Gebbia, V.

**Texeira, L. C.** See Bruno, S.

**Thurer, R. J.** See Flores, M. R.

**Tinari, N.** See Iacobelli, S.

**Tobe, S. W.** See Warner, E.

**Tomiak, E.** See Evans, W. K.

**Toner, G.** See Olver, I.

**Topuz, E.** See Aydiner, A.

**Torkelson, J.** See Kennedy, B. J.

**Tormey, D. C.** See Gertz, M. A.

**Trachtenberg, J.** See Warner, E.

**Tralins, A. H.**  
—Lactation after conservative breast surgery combined with radiation therapy, 40

**Tsubota, A.** See Ikeda, K.

**Tuason, L.** See Kalaycioglu, M. E.

**Uchino, J.** See Kawata, A.

**Ueno, N. T.**

—Zukiwski, A. A.: Combination recombinant interleukin-2, recombinant interferon- $\alpha$ , and 5-fluorouracil for treatment of metastatic renal cell carcinoma, 358

**Une, Y.** See Kawata, A.

**Vaira, F.** See Pronzato, P.

**Valdivieso, M.** See LoRusso, P. M.

**Valenza, R.** See Gebbia, V.

**Vallejo, C. T.**  
—Rabinovich, M. G.; Perez, J. E.; Rodriguez, R.; Machiavelli, M. R.; Leone, B. A.; Romero, A. D.; Lacava, J. A.; Cuevas, M. A.; Langhi, M. J.; Romero Acuña, L. A.; Romero Acuña, J.; Amato, S.; Barbieri, M. R.: High-dose cisplatin with dipyridamole in advanced non-small cell lung cancer, 185

**Valori, V.** See Golucci, G.

**van Assendelft, P. J.** See van Mierlo, I. J.

**Van Belle, S.** See Van Lancker, M.

**Van Lancker, M.** See Coen, V.

—Goor, C.; Sacre, R.; Lamote, J.; Van Belle, S.; De Coene, N.; Roelstraete, A.; Storme, G.: Patterns of axillary lymph node metastasis in breast cancer, 267

**van Mierlo, I. J.**  
—Levendag, P. C.; Eijkenboom, W. M. H.; Jansen, P. P.; Meeuwis, C. A.; van Assendelft, P. J.; van Putten, W. L. J.; Nowak, P. J. C. M.: Radiation therapy for cancer of the piriiform sinus, 502

**Van Poppel, H.** See Vandenbroucke, F.

**van Putten, W. L. J.** See van Mierlo, I. J. M.

**Vandenbroucke, F.**  
—Van Poppel, H.; Derluyn, J.; Popelier, G.; Casselman, J.; Billiet, I.; Vanuytsel, L.; Paridaens, R.; Baert, L.: Interim results on a randomized trial of mitomycin C in combination with orchidectomy for newly diagnosed metastatic prostate cancer, 263

**Vanuytsel, L.** See Vandenbroucke, F.

**Varthalitis, J.** See Pectasides, D.

**Velasco, E.**  
—Costa, M. A.; Martins, C. A.; Nucci, M.: Randomized trial comparing oral ciprofloxacin plus penicillin V with amikacin plus carbencillin or ceftazidime for empirical treatment of febrile neutropenic cancer patients, 429

## AUTHOR INDEX

**Veltri, E.** See Arcangeli, G.; Di Leo, A.  
**Vetter, W.** See Stey, C.  
**Vicario, G.** See Iacobelli, S.  
**Vidal-Jové, J.** See Fernández-Trigo, V.  
**Vigani, A.** See Pronzato, P.  
**Vuillemin, E.** See Antoine, E. C.  
**Wakizaka, Y.** See Kawata, A.  
**Warmelink, C.** See Forman, J. D.  
**Warner, E.**  
—Tobe, S. W.; Andrusis, I. L.; Pei, Y.; Trachtenberg, J.; Skorecki, K. L.: Phase I-II study of vinblastine and oral cyclosporin A in metastatic renal cell carcinoma, 251  
**Watkins, K.** See Keung, Y.-K.  
**Weil, M.** See Antoine, E. C.  
**Weiser, S.** See Klocker, J.  
**Weiss, G. R.** See Marshall, M. E.  
**White, D. A.** See Rivera, M. P.  
**Wieand, H. S.** See Ingle, J. N.

**Wilgus, L.** See McClay, E. F.  
**Williams, L.** See Look, K. Y.  
**Williamson, S. K.**  
—Tangen, C. M.; Maddox, A.-M.; Spiridonidis, C. H.; MacDonald, J. S.: Phase II evaluation of low-dose continuous 5-fluorouracil and weekly cisplatin in advanced adenocarcinoma of the stomach, 484  
**Wilson, J. W.** See Agarwala, S. S.  
**Wolf, M. K.** See Marshall, M. E.  
**Woodcock, T.** See Joseph, G.  
**Yamane, E.** See Nishida, K.  
**Yoneda, M.** See Nishida, K.  
**Yoshikawa, T.** See Nishida, K.  
**Yudelov, M.** See Forman, J. D.  
**Zeigler, Z.** See Nemunaitis, J.  
**Zimet, A.** See Olver, I.  
**Zukiwski, A. A.** See Ueno, N. T.

Statement of Ownership, Management, and Circulation (Required by 39 U.S.C. 3685)									
1 Publication Title: American Journal of Clinical Oncology: American Clinical Trials		2 Publication No: 0 2 7 7 - 3 7 3 2		3 Filing Date: October 1, 1995					
4 Issue Frequency: Bimonthly		5 No. of Issues Published Annually: 6		6 Annual Subscription Price: \$218 US/ \$262 Foreign					
7 Complete Mailing Address of Known Office of Publication (Street, City, County, State, and ZIP+4; Not Printer): 12107 Insurance Way, Hagerstown MD 21740									
8 Complete Mailing Address of Headquarters or General Business Office of Publisher (Not Printer): 12107 Insurance Way, Hagerstown MD 21740									
9 Full Name and Complete Mailing Address of Publisher, Editor, and Managing Editor (Do Not Leave Blank): Publisher Name and Complete Mailing Address: Lippincott-Raven Publishers, 227 E. Washington Square, Philadelphia PA 19106									
10 Editor (Name and Complete Mailing Address): Dr. Lutcher M. Brady, Dept. of Radiation Oncology and Nuclear Medicine, Hahnemann University, Broad and Vine Streets, MS 2000, Philadelphia PA 19102									
11 Managing Editor (Name and Complete Mailing Address): Greg Fagan, Lippincott-Raven Publishers, 1185 Ave of the Americas, NY, NY 10036									
12 Owner (If owned by a corporation, its name and address must be stated and no immediate parent, the names and addresses of stockholders owning or holding 1 percent or more of the total amount of stock. If not owned by a corporation, the name and address of the individual owner must be given. If the publication is published by a partnership or other legal entity, its name and address must be given. If the publication is published by a nonprofit organization, its name and address must be stated.) (Do Not Leave Blank.)									
Full Name: Lippincott-Raven Publishers		Complete Mailing Address: 227 E. Washington Square, Philadelphia PA 19106							
Wolters Kluwer US		1185 Avenue of the Americas NY, NY 10036							
Wolters Kluwer nv (owns 100% of stock)		Stadhouderskade 1 1054 FS Amsterdam, The Netherlands							
13 Known Stockholders, Mortgagors, and Other Security Holders Owning or Holding 1 Percent or More of Total Amount of Bonds, Mortgages, or Other Securities (If none, check here) <input type="checkbox"/> None									
Full Name:		Complete Mailing Address:							
None									
14 For completion by non-profit organizations who are required to mail at special rates. The purpose, function, and nonprofit status of this organization and the exempt status for federal income tax purposes. (Check one) <input type="checkbox"/> Has Not Changed During Previous 12 Months <input type="checkbox"/> Has Changed During Previous 12 Months <input type="checkbox"/> If changed, publisher must submit explanation of change with this statement									

PS Form 3529, October 1994

(See Instructions on Reverse.)

American Journal of Clinical Oncology			V 18 #3	
15	Extent and Nature of Circulation	Average No. Copies Each Issue During Preceding 12 Months	Actual No. Copies of Single Issue Published Nearest to Filing Date	
a	Total No. Copies Avail Post Net	2258	2276	
b	Post or Requesst of Requested Circulation (1) Same as Above and Carriers, Street Vendors, and Counter Sales	1373	1357	
c	Post or Requesst of Requested Circulation (2) Paid and/or Advertisers, Print Copies Exchange Copies	1373	1357	
d	Total Post and/or Requested Circulation (Sum of 15a, 15b, and 15c, 20)	159	167	
e	Free Distribution by Mail (Society, Comptemporary, and Other Free)	159	167	
f	Free Distribution Outside the Mail (Carriers or Other Means)			
g	Total Free Distribution (Sum of 15d and 15e)	159	167	
h	Total Distribution (Sum of 15a and 15d)	1532	1524	
i	Copies Not Distributed (1) Return from News Agents	726	752	
j	Total Post Distribution (Sum of 15a and 15d)	2258	2276	
k	Percent Postage or Requested Circulation (15c / 15d x 100)	89%	89%	
16 This Statement of Ownership will be printed on the <b>V 18 #5</b> issue of this publication. <input type="checkbox"/> Check box if not required to publish				
17 Signature and Title of Editor, Publisher, Business Manager, or Owner <i>Paul J. Pasquetti</i> Operations Manager 9/21/95				
I certify that all information furnished on this form is true and complete. I understand that anyone who furnishes false or misleading information on this form or omits material or information requested on the form may be subject to criminal sanctions (including fines and imprisonment) and/or civil sanctions including monetary damages and civil penalties.				

## Instructions to Publishers

- 1 Complete and file one copy of this form with your postmaster on or before October 1 annually. Keep a copy of the completed form for your records.
- 2 Include in items 10 and 11, in cases where the stockholder or security holder is a trustee, the name of the person or corporation for whom the trustee is acting. Also include the names and addresses of individuals who are stockholders who own or hold 1 percent or more of the total amount of bonds, mortgages, or other securities of the publishing corporation. In item 11, if none, check box. Use blank sheets if more space is required.
- 3 Be sure to furnish all information called for in item 15 regarding circulation. Free circulation must be shown in items 15d, e, and f.
- 4 If the publication had second-class authorization as a general or requester publication, this Statement of Ownership, Management, and Circulation must be published; it must be printed in any issue in October or the first printed issue after October if the publication is not published during October.
- 5 In item 16, indicate date of the issue in which this Statement of Ownership will be printed.
- 6 Item 17 must be signed.

Failure to file or publish a statement of ownership may lead to suspension of second-class authorization.

PS Form 3529, October 1994 (Reverse)

## SUBJECT INDEX

Acral lesion, basal cell carcinoma and, 176  
Adriamycin, See also Doxorubicin  
    with interleukin-2 and lymphokine-activated killer cells, versus adriamycin alone, in hepatocellular cancer, 257  
    with vincristine  
        and cyclophosphamide and dacarbazine, in uterine sarcoma, 282  
        and dexamethasone, compared to VAD plus interferon, in multiple myeloma, 475  
AIDS, lung cancer and, 59  
Amikacin with penicillin V, ciprofloxacin, and carbenicillin or cefazidime, in febrile neutropenia, 429  
Aminoglycoside therapy, in febrile neutropenia, 429  
Aminothiadiazole, in leiomyosarcoma of uterine corpus, 397  
Anal canal, cancer of, 32  
Aneuploidy, in gastric cancer, 325  
Anthracycline therapy, cardiac toxicity and, 444  
Anticoagulants, cancer incidence and mortality in patients treated with, 15  
Appendiceal cancer, chemoresistance-sensitivity assay for, 454  
Aromatase inhibitors, in breast cancer, 407  
Arterial embolization, transcatheter, in hepatoma, 204  
Astrocytoma  
    carboplatin, 5-fluorouracil, and radiation in, 1 thermoradiotherapy in, 510  
  
Basal cell carcinoma, presenting as finger mass, 176  
Biological therapy, in pancreatic adenocarcinoma, 525  
Biopsy, endoscopic, flow cytometric analysis of nuclear DNA content in gastric cancer and, 325  
Bladder cancer, interleukin-2 in, 100  
Bleomycin  
    with carboplatin and radiotherapy, in head and neck cancer, 52  
    in peritoneal mesothelioma after thorotrast exposure, 313  
Bone, giant cell tumor of, 144  
Bone marrow transplant  
    in breast cancer, 491  
    central venous catheter-related infections in, 469  
Guillain-Barre syndrome after, 167  
    in leukemia, esophageal cancer after, 343  
Book review  
    *Clinical Flow Cytometry: Principles and Application* (by Bauer, KD et al), 90  
    *Handbook of Flow Cytometry Methods* (Darzynkiewicz Z et al, eds), 90  
    *Lung Cancer Differentiation: Implications for Diagnosis and Treatment* (Bernal S and Hesketh P, eds), 90  
Brachytherapy, in breast cancer, 331, 348, 353  
Brain tumor, thermoradiotherapy in, 510  
Breast cancer  
    aromatase inhibitors in, 407  
    axillary lymph node metastasis in, 267  
    bone marrow transplantation in, Guillain-Barre syndrome after, 167  
    brachytherapy in, 331, 348, 353  
    busulfan, cyclophosphamide, and bone marrow transplant and/or peripheral blood progenitor cell rescue in, 491  
    inflammatory, tamoxifen in, 74  
    lactation after surgery and radiation in, 40  
    mesna with ifosfamide in, 498  
    small-cell, primary, neuroendocrine, 133  
    spontaneous tumor lysis syndrome and, 71  
    thiotepa, with 5-fluorouracil, and folinic acid in, 385  
Breast-feeding, after surgery and radiation in breast cancer, 40  
Busulfan, with cyclophosphamide, and bone marrow transplant and/or peripheral blood progenitor cell rescue, in breast cancer, 491  
  
Carbenicillin, with ciprofloxacin, and penicillin V with amikacin, in febrile neutropenia, 429  
Carboplatin  
    with bleomycin and radiotherapy, in head and neck cancer, 52  
    with etoposide  
        and granulocyte macrophage-colony stimulating factors, in ovarian cancer, 23  
    in leukemia, 382  
    in small cell lung cancer, elderly patient and, 149  
    with 5-fluorouracil and radiation, in glioma, 1  
    with methotrexate  
        in urothelial cancer, 78  
        and vinblastine, in bladder cancer, 223  
    and radiotherapy, in head and neck cancer, 273  
Cardiac toxicity, epirubicin and, 444  
Castleman's disease, multicentric, 180  
Catheter, infection related to, 469  
Ceftazidime, with ciprofloxacin, and penicillin V with amikacin, in febrile neutropenia, 429  
Cervical cancer  
    nonsquamous cell, 495  
    squamous cell, fazarabine in, 439  
Chemodectomy, of head and neck, radiotherapy in, 389  
Chemoresistance-sensitivity assay, for colorectal and appendiceal cancer, 454  
Chemotherapy  
    acute dyspnea related to, 245  
    acute myocardial infarction after, 444  
    in advanced nonseminomatous testicular cancer, 463  
    in anal canal carcinoma, 32  
    in basal cell finger carcinoma, 176  
    in bladder cancer, 100, 223  
    in breast cancer, 71, 74, 133, 385, 392, 491, 498  
    in cervical cancer, 439, 441  
    in colorectal cancer, 118, 158, 300  
    in esophageal cancer, 216  
    in extraskeletal myxoid chondrosarcoma, 161  
    in febrile neutropenia, 429  
    in gastric cancer, 318, 484, 519  
    in giant cell tumor of bone, 144  
    in head and neck cancer, 52, 273, 293, 425  
    in hepatic lymphoma and epidermoid lung cancer, 194  
    in hepatocellular cancer, 257  
    in hepatoma, 204  
    in high-grade gliomas, 1  
    immunotherapy and  
        in hepatocellular cancer, 257  
        in metastatic melanoma, 421  
    interferon after, in small-cell lung cancer, 67  
        in leiomyosarcoma of uterine corpus, 397  
        in leukemia, 83, 105, 382  
        myeloid, older patient and, 105

lorazepam for toxicity of, 170  
 in lung cancer  
     epidermoid, hepatic lymphoma and, 194  
     with human immunodeficiency virus, 56  
     non-small cell, 185, 303  
     small cell, 67, 118, 149  
 in lymphoma, 8, 44  
     hepatic, epidermoid lung cancer and, 194  
     non-Hodgkin, 8  
 in malignant melanoma, 56, 421, 488  
 in Merkel cell carcinoma, 418  
 in multiple myeloma, 475  
 in myelodysplastic syndrome, 189  
 in myeloid leukemia, 83, 105  
 in myxoid chondrosarcoma, 161  
 in myxoid malignant fibrous histiocytoma, 525  
 in nasopharyngeal carcinoma, 139  
 in non-Hodgkin lymphoma, 8  
 in non-small cell cancer, 47  
 in non-small cell lung cancer, 185, 303  
 oral ulceration and, 403  
 orchidectomy and, in prostate cancer, 263  
 in osteosarcoma, 93  
 in ovarian cancer, 19, 23, 156, 164  
 in peritoneal mesothelioma after thorotrust exposure, 313  
 in prostate cancer, 239, 263, 400  
 radiotherapy and  
     in rectal tumors, 369  
     in squamous cell carcinoma of head and neck, 425  
     in squamous cell esophageal cancer, 376  
 in renal cell cancer, 211, 251, 358  
 in small cell lung cancer, 67, 118, 149  
 in squamous cell cervical cancer, 439, 441  
 with thymostimulin, in non-Hodgkin lymphoma, 8  
 toxicity of, 245, 382, 403, 444  
 triple infusion, in older patients with acute myeloid leukemia, 105  
 in urothelial carcinoma, 78  
 in uterine cancer, 282, 397  
**CCHIP**, in prostate cancer, 400  
**Chondrosarcoma**  
     myxoid, extraskeletal, 161  
     of rib, after repetitive low-impact trauma, 87  
**Chronotherapy**, 27  
**Ciprofloxacin**  
     with penicillin V with amikacin, and carbenicillin or ceftazidime, in febrile neutropenia, 429  
     with pentoxifylline, in myelodysplastic syndrome, 189  
**Circadian-rhythm modulated rate continuous venous infusion**, in interferon administered as, 27  
**Cisplatin**  
     with cytarabine, in metastatic colorectal cancer, 158  
     with dipyridamole, in non-small cell lung cancer, 185  
     with doxorubicin  
         and etoposide, in gastric cancer, 318  
         and surgical debulking, in giant cell tumor of bone, 144  
     with etoposide  
         in colorectal cancer, 300  
         and doxorubicin, in gastric cancer, 318  
     with 5-fluorouracil, in advanced gastric cancer, 484  
     with ifosfamide, in non-small cell lung cancer, 303  
     lorazepam for toxicity induced by, 170  
     with tamoxifen and immunotherapy, in metastatic melanoma, 421  
     with vindesine, hyaluronidase, and radiotherapy, in squamous cell carcinoma of head and neck, 425  
     with vinorelbine, in squamous cell carcinoma of head and neck, 293  
**Colon cancer**, monoclonal antibody in, 307  
**Colorectal cancer**  
     chemoresistance-sensitivity assay for, 454  
     cisplatin  
         with cytarabine in, 158  
         with etoposide in, 300  
     5-fluorouracil with folinic acid, versus 5-fluorouracil with cyclophosphamide and mitomycin C in, 118  
     isotretinoin with interferon in, 436  
**Computed tomography**, in peritoneal mesothelioma after thorotrust exposure, 313  
**Counseling**, patient, prostate cancer and, 532  
**Cutaneous neuroendocrine carcinoma**, 199  
**Cyclophosphamide**  
     with busulfan, and bone marrow transplant and/or peripheral blood progenitor cell rescue, in breast cancer, 491  
     with 5-fluorouracil and mitomycin C, versus 5-fluorouracil with folinic acid, in colorectal cancer, 118  
     with vincristine, Adriamycin, and dacarbazine, in uterine sarcoma, 282  
**Cyclosporin A**, with vinblastine, in renal cell cancer, 251  
**Cytarabine**, with cisplatin, in metastatic colorectal cancer, 158  
**Cytokines**, viral resistance and, 226  
**Dacarbazine**, with cyclophosphamide, vincristine, and Adriamycin, in uterine sarcoma, 282  
**Dexamethasone**, with vincristine, and Adriamycin, compared to VAD plus interferon, in multiple myeloma, 475  
**Dipyridamole**, with cisplatin, in non-small cell lung cancer, 185  
**DNA content**, in endoscopic biopsy tissue of gastric cancer, 325  
**Doxorubicin**, See also Adriamycin  
     with cisplatin  
         and etoposide, in gastric cancer, 318  
         and surgical debulking, in giant cell tumor of bone, 144  
     in myxoid malignant fibrous histiocytoma, 525  
**Dysgerminoma**, suprasellar, myeloid leukemia and, 83  
**Dyspnea**, related to combined mitomycin plus vinca alkaloid chemotherapy, 245  
**Edatrexate**, in previously treated ovarian cancer, 164  
**Eldery**, myeloid leukemia in, 105  
**Emesis**, lorazepam and, 170  
**Enterocolitis**, after etoposide with carboplatin for acute leukemia, 382  
**Epidermal growth factor mouthwash**, in cytotoxic-induced oral ulceration, 403  
**Epidermal lung cancer**, hepatic lymphoma and, 194  
**Epidoxorubicin**  
     with combination chemotherapy, in non-Hodgkin lymphoma, 8  
     with 5-fluorouracil and folinic acid, versus folinic acid with 5-fluorouracil, in gastric cancer, 519  
**Epirubicin**  
     with medroxyprogesterone, in prostate cancer, 239  
     in non-Hodgkin lymphoma, myocardial infarction after, 444  
**EPOCH**, in lymphoma, 44  
**Erratum**: A Randomized Clinical Trial in Bronchogenic Small-Cell Carcinoma Evaluating Alternating Maintenance Therapy of Vincristine, Adriamycin, Procarbazine, and Etoposide (VAPE) with Cyclophosphamide, CCNU, and Methotrexate (CCM) versus CCM Maintenance Alone in Complete Responders Following VAPE Induction and Late Intensification, 462  
**Esophageal cancer**  
     after allogeneic bone marrow transplant for acute leukemia, 343  
     immunotherapy in, 216  
     radiotherapy alone versus radiotherapy and chemotherapy in, 376  
**Estrogen**, aromatase inhibitors and, 407

**Etoposide**  
 with carboplatin  
   and granulocyte macrophage-colony stimulating factors, in  
     ovarian cancer, 23  
     in leukemia, 382  
     in Merkel cell carcinoma, 418  
     in small cell lung cancer, elderly patient and, 149  
 with cisplatin  
   in colorectal cancer, 300  
   and doxorubicin, in gastric cancer, 318

**Fazarabine**  
 in ovarian cancer, 156  
 in squamous cell cervical cancer, 439

**Finger, basal cell carcinoma of**, 176

**Flow cytometry**, in gastric cancer, 325

**5-Fluorouracil**  
 with carboplatin and radiation, in glioma, 1  
 chemoresistance-sensitivity assay for, 454  
 with cisplatin, in advanced gastric cancer, 484  
 with folinic acid  
   versus 5-fluorouracil with cyclophosphamide and mitomycin C,  
     in colorectal cancer, 118  
     in small cell lung cancer, 130  
     and thiotepa, in breast cancer, 385  
 with hyperfractionated radiotherapy, in rectal tumors, 369  
 with interleukin-2 and interferon, in renal cell cancer, 358  
 with leucovorin, in epithelial ovarian cancer, 19  
 plus 4-epidoxorubicin with folinic acid, versus folinic acid with 5-fluorouracil, in gastric cancer, 519

**Folinic acid**, with 5-fluorouracil  
 versus 5-fluorouracil with cyclophosphamide and mitomycin C,  
   in colorectal cancer, 118  
 versus folinic acid with 5-fluorouracil plus 4-epidoxorubicin, in  
   gastric cancer, 519  
 in small-cell lung cancer, 130  
 and thiotepa, in breast cancer, 385

**Gallium nitrate**, in nonsquamous cell cervical cancer, 495

**Gastric cancer**  
 doxorubicin, etoposide, and cisplatin in, 318  
 flow cytometric analysis of nuclear DNA content in biopsy tissue  
   of, 325  
 5-fluorouracil  
   with cisplatin in, 484  
   with epidoxorubicin and folinic acid, versus folinic acid with 5-fluorouracil, 519

**Giant cell tumor of bone**, 144

**Glioma**  
 radiotherapy in, 449  
 thermoradiotherapy in, 510

**Glomus tumor**, of head and neck, radiotherapy in, 389

**Granulocyte macrophage-colony stimulating factors**, with etoposide, and carboplatin, in ovarian cancer, 23

**Guillain-Barre syndrome**, after autologous bone marrow transplantation, 167

**Head and neck cancer**  
 radiotherapy in  
   carboplatin and, 273  
     with bleomycin, 52  
     piriform sinus and, 498  
   squamous cell  
     cisplatin  
       with vindesine, hyaluronidase, and radiotherapy in, 425  
       with vinorelbine in, 293  
     untreated, 363

**Heart disease, cancer incidence and mortality in patients with**, 15

**Hepatic lymphoma, epidermoid lung cancer and**, 194

**Hepatocellular cancer**  
 adjuvant chemoimmunotherapy in, 257  
 beta-interferon and menagoril in, 287

**Hepatoma**, tegafur and uracil in, 204

**Histiocytoma, fibrous, malignant, myxoid**, chemotherapy in, 525

**Hodgkin disease**, infusional chemotherapy in, 44

**Hormonal therapy**, aromatase inhibitors in, 407

**Hormone receptors**, in metastatic inflammatory breast cancer, 74

**Human immunodeficiency virus**, lung cancer and, 59

**Hyaluronidase**, with cisplatin, vindesine, and radiotherapy, in squamous cell carcinoma of head and neck, 425

**Hypercalcemia**, humeral, rectal adenocarcinoma and, 126

**Hyperthermia, interstitial**, in brain tumor, 510

**Ifosfamide**  
 with cisplatin, in non-small cell lung cancer, 303  
 with mesna, in breast cancer, 498

**Immunconjugate**, in colon cancer, 307

**Immunotherapy**  
 in bladder cancer, 100  
 and chemotherapy, in metastatic melanoma, 421  
 in esophageal cancer, 216  
 in hepatocellular cancer, 257, 287  
 with interferon, 27  
 intralymphatic, resistance to common viruses during, 226

**Infection**, catheter-related, bone marrow transplant and, 469

**Infusional therapy**, in lymphoma, 44

**Interferon**  
 following combination chemotherapy, in small-cell lung cancer, 67  
 with interleukin-2 and 5-fluorouracil, in renal cell cancer, 358  
 with isotretinoin, in metastatic colorectal cancer, 436  
 with menagoril, in hepatocellular cancer, 287  
 with retinoic acid, in pancreatic adenocarcinoma, 525  
 as seven-day continuous venous infusion at circadian-rhythm modulated rate, 27

**Interleukin-2**  
 with Adriamycin and lymphokine-activated killer cells, versus  
   adriamycin alone, in hepatocellular cancer, 257  
 in bladder cancer, 100  
 with interferon and 5-fluorouracil, in renal cell cancer, 358  
 with tumor necrosis factor, in non-small cell lung cancer, 47

**Interperitoneal therapy**, in ovarian cancer, 23

**Iodine-125**, in breast cancer, 353

**Iridium-192**, in breast cancer, 353

**Isotretinoin**, with interferon, in metastatic colorectal cancer, 436

**Lactation**, after breast surgery, and radiation therapy, 40

**Leiomyosarcoma**, of uterine corpus, aminothiadiazole in, 397

**Leucovorin**, with 5-fluorouracil, in epithelial ovarian cancer, 19

**Leukemia**  
 bone marrow transplant in, esophageal cancer after, 343  
 carboplatin and etoposide in, 382  
 myeloid  
   in elderly, 105  
   suprasellar dysgerminoma and, 83

**Leukopenia**, methotrexate with carboplatin and, 78

**Liposome therapy**, in osteosarcoma, 93

**Lorazepam**, for cisplatin-induced toxicity, 170

**Lung cancer**  
 epidermoid, hepatic lymphoma and, 194  
 human immunodeficiency virus and, 59  
 non-small cell  
   dipyridamole with cisplatin in, 185  
   ifosfamide with cisplatin in, 303

interleukin-2 and tumor necrosis factor in, 47  
radiotherapy in, prognostic factors and, 111

small-cell  
carboplatin and etoposide in, elderly patient and, 149  
5-fluorouracil and folinic acid in, 130  
interferon after combination chemotherapy in, 67

Lymph node metastases, in breast cancer, 267  
Lymphokine-activated killer cells, with Adriamycin and interleukin-2, versus Adriamycin alone, in hepatocellular cancer, 257

Lymphoma  
hepatocellular, epidermoid lung cancer and, 194  
infusional chemotherapy in, 44  
non-Hodgkin, acute myocardial infarction after epirubicin in, 444

Magnetic resonance imaging, in high-grade glioma treated with radiotherapy, 297

Massage, prostate bed, after radical prostatectomy, 481

Medroxyprogesterone, with epirubicin, in prostate cancer, 239

Melanoma, malignant  
metastatic, zeniplatin in, 56  
piritrexim and DTIC in, 488

Menagoril, and interferon, in hepatocellular cancer, 287

Merbarone, in squamous cell cervical cancer, 441

Merkel cell carcinoma, 199  
carboplatin and etoposide in, 418

Mesna, with ifosfamide, in breast cancer, 498

Mesothelioma, peritoneal, thorotrust exposure and, 313

Methotrexate, with carboplatin  
in urothelial cancer, 78  
and vinblastine, in bladder cancer, 223

Metoclopramide, for cisplatin-induced toxicity, 170

Mitomycin  
chemoresistance-sensitivity assay for, 454  
with cyclophosphamide and 5-fluorouracil, versus 5-fluorouracil with folinic acid, in colorectal cancer, 118  
with orthorectomy, in prostate cancer, 263  
with vinca alkaloid chemotherapy, acute dyspnea related to, 245

Monoclonal antibody, in colon cancer, 307

Multiple myeloma, vincristine, Adriamycin, and dexamethasone, compared to VAD plus interferon in, 475

Muramyl tripeptide phosphatidylethanolamine, in osteosarcoma, 93

Myelodysplastic syndrome, pentoxifylline with ciprofloxacin in, 189

Myeloid leukemia  
in elderly, 105  
suprasellar dysegerminoma and, 83

Myocardial infarction, after epirubicin for non-Hodgkin lymphoma, 444

Myxoid chondrosarcoma, extraskeletal, 161

Myxoid malignant fibrous histiocytoma, chemotherapy in, 525

Nasopharyngeal cancer  
neoadjuvant chemotherapy in, 139  
radiotherapy in, 337

Navelbine See Vinorelbine

Nephrotoxicity, of ondansetron, 56

Neuroendocrine carcinoma, cutaneous, 199

Neuropeptides, neuroendocrine primary small cell breast cancer and, 133

Neutropenia, febrile, ciprofloxacin, and penicillin V with amikacin, and carbencillin or ceftazidime in, 429

Non-Hodgkin lymphoma  
epirubicin in, myocardial infarction after, 444  
thymostimulin and combination chemotherapy in, 8

Non-small cell lung cancer  
dipyridamole and cisplatin in, 185  
ifosfamide and cisplatin in, 303

interleukin-2 and tumor necrosis factor in, 47  
radiotherapy in, prognostic factors and, 111

Nonsquamous cell carcinoma, cervical, 495

Oat cell carcinoma, neuroendocrine primary small cell breast cancer and, 133

Ondansetron, nephrotoxicity of, 56

Orthorectomy, and mitomycin, in prostate cancer, 263

Osteosarcoma, liposome therapy in, 93

Ovarian cancer  
carboplatin, etoposide, and granulocyte macrophage-colony stimulating factors in, 23  
edatrexate in, 164  
fazarabine in, 156  
leucovorin and 5-fluorouracil in, 19

Pancreatic adenocarcinoma, interferon and retinoic acid in, 525

Parathyroid hormone related peptide, humeral hypercalcemia associated with rectal adenocarcinoma and, 126

Penicillin V with amikacin, and ciprofloxacin, with carbencillin or ceftazidime, in febrile neutropenia, 429

Pentoxifylline, with ciprofloxacin, in myelodysplastic syndrome, 189

Peripheral blood progenitor cell rescue, in breast cancer, 491

Piriform sinus cancer, radiotherapy in, 498

Piritexim, with DTIC, in malignant melanoma, 488

Prostate cancer  
CHIP in, 400  
conformal neutron and photon radiotherapy in, 231  
mitomycin C, and orchidectomy in, 263  
patient counseling in, 532  
prostate bed massage after radical prostatectomy and, 475

Prostate specific antigen, after radical prostatectomy, prostate bed massage and, 475

Prostatectomy, radical, prostate bed massage after, 475

Quinidine, with vinblastine, in metastatic renal cell carcinoma, 211

Radiosensitivity, lactation and, 40

Radiotherapy  
in advanced chemodectomy of head and neck, 389  
in cancer of piriform sinus, 498  
with carboplatin  
and bleomycin, in head and neck cancer, 52  
and 5-fluorouracil, in glioma, 1  
in head and neck cancer, 273  
chemotherapy and, in squamous cell carcinoma of head and neck, 425  
in esophageal cancer, 216  
with 5-fluorouracil, in rectal tumors, 369  
in head and neck cancer, 52, 273, 389, 425, 498  
hyperfractionated, in malignant glioma, 449  
lactation after breast surgery and, 40  
neutron and photon, in prostate adenocarcinoma, 231  
in non-small cell lung cancer, prognostic factors in, 111  
in opharyngeal cancer, 337  
in rectal cancer, 277  
in squamous cell esophageal cancer, 376

Rectal cancer  
humeral hypercalcemia and, 126  
isotretinoin and interferon in, 436  
radiotherapy in, 277

Rectal tumors, 5-fluorouracil and hyperfractionated radiotherapy in, 369

Renal cell cancer  
cyclosporin A with mitomycin in, 251  
interleukin-2, 5-fluorouracil, and interferon in, 358  
vinblastine and quinidine in, 211

Retinoic acid, with interferon, in pancreatic adenocarcinoma, 525  
Retinoids  
  in colorectal cancer, 436  
  with interferon, in pancreatic adenocarcinoma, 525  
Rib, chondrosarcoma of, after repetitive low-impact trauma, 87

Salvage therapy, infusional therapy as, 44  
Sarcoma, uterine, cyclophosphamide with vincristine, adriamycin, and dacarbazine in, 282  
Skin cancer, basal cell carcinoma and, 176  
Small-cell cancer  
  breast, primary, neuroendocrine, 133  
  bronchogenic (erratum), 462  
  lung  
    carboplatin and etoposide in, elderly patient and, 149  
    5-fluorouracil and folinic acid in, 130  
    interferon after combination chemotherapy in, 67

Squamous cell carcinoma  
  cervical  
    fazarabine in, 439  
    merbarone in, 441  
  esophageal, radiotherapy alone versus radiotherapy and chemotherapy in, 376  
  of head and neck, untreated, 363  
Suprasellar dysgerminoma, myeloid leukemia and, 83

Tamoxifen  
  with cisplatin and immunotherapy, in metastatic melanoma, 421  
  in inflammatory breast cancer, 74

Tegafur, with uracil, in hepatoma, 204

Testicular cancer, optimal number of chemotherapy courses in, 463

Thermoradiotherapy, in brain tumor, 510

Thiotepa, with 5-fluorouracil, and folinic acid, in breast cancer, 385

Thorotrust malignancy, peritoneal mesothelioma as, 313

Thrombocytopenia, methotrexate with carboplatin and, 78

Thymic hormones, with combination chemotherapy, in non-Hodgkin lymphoma, 8

Thymostimulin, with combination chemotherapy, in non-Hodgkin lymphoma, 8

Trauma, repetitive, chondrosarcoma of rib and, 87

Tumor lysis syndrome, spontaneous, breast cancer and, 71

Tumor necrosis factor, with interleukin-2, in non-small cell lung cancer, 47

Ulceration, oral, epidermal growth factor mouthwash in, 403

Uracil, with tegafur, in hepatoma, 204

Urothelial cancer, methotrexate and carboplatin in, 78

Uterine corpus, leiomyosarcoma of, aminothiadiazole in, 397

Uterus, sarcoma of, cyclophosphamide with vincristine, adriamycin, and dacarbazine in, 282

Vinblastine  
  with carboplatin and methotrexate, in bladder cancer, 223  
  with cyclosporin A, in renal cell cancer, 251  
  with mitomycin, acute dyspnea related to, 245  
  with quinidine, in metastatic renal cell carcinoma, 211

Vinca alkaloid chemotherapy, with mitomycin, acute dyspnea related to, 245

Vincristine, with adriamycin  
  and cyclophosphamide, and dacarbazine, in uterine sarcoma, 282  
  and dexamethasone, compared to VAD plus interferon, in multiple myeloma, 475

Vindesine  
  with cisplatin, hyaluronidase, and radiotherapy, in squamous cell carcinoma of head and neck, 425  
  with mitomycin, acute dyspnea related to, 245

Vinorelbine  
  in breast cancer, 392  
  with cisplatin, in squamous cell carcinoma of head and neck, 293  
  with mitomycin, acute dyspnea related to, 245

Virus, resistance to, during intralymphatic immunotherapy, 226

Volar surface lesion, basal cell carcinoma and, 176

Xomazyme 791, in colon cancer, 307

Zeniplatin, in metastatic melanoma, 56